Peer Exchange


Evolving Treatment Landscape in Myelodysplastic Syndromes

December 13th 2023

A panel of hematologist-oncologists provides an overview of the diagnosis and treatment of myelodysplastic syndromes (MDS) and offers comprehensive insights on the evolving treatment landscape.

Transforming Outcomes in AL Amyloidosis with Precision Medicine and Targeted Therapies

December 13th 2023

A team of expert oncologists delves into the latest developments in treating AL amyloidosis, placing particular emphasis on innovative therapies aimed at targeting amyloid deposits.

Advances in the Treatment of Multiple Myeloma: Highlights from ASH 2023 and Beyond

December 13th 2023

Recent Updates in the Treatment of Follicular Lymphoma and Mantle Cell Lymphoma

December 13th 2023

A panel of experts discuss recent updates including new data from ASH 2023 on the treatment of follicular lymphoma and mantle cell lymphoma as well as their clinical implications.

Optimizing Outcomes in Allogeneic Transplants

December 13th 2023

Polycythemia Vera and Myelofibrosis: Current and Future Standards of Care

December 13th 2023

Experts discuss several recent data updates in polycythemia vera and myelofibrosis in the context of the treatment landscape and its impact on clinical practice.

New Treatment Options for DLBCL: Impact on Sequencing Therapeutic Choices

December 13th 2023

ASH 2023: Exploring Therapeutic Advancements for Chronic Lymphocytic Leukemia

December 13th 2023

A panel of expert oncologists explore advancements in the treatment of CLL, reviewing recent data updates from ASH 2023 and their potential impact on clinical practice.

Advancements in the Treatment of Desmoid Tumors

December 13th 2023

A panel of expert oncologists explore recent advancements in the treatment of desmoid tumors, highlighting the approval of nirogacestat as the first FDA-approved in this treatment setting, and discussing its impact on clinical practice.

Precision Medicine: Biomarker Testing and Uncommon EGFR Mutations in NSCLC

November 16th 2023

Expert panelists review recent advances in biomarker testing and the treatment landscape of uncommon EGFR mutations in non–small cell lung cancer.

The Evolving Treatment Paradigm of Advanced Non–Small Cell Lung Cancer: Where Are We in 2023?

October 31st 2023

A panel of experts on advanced non–small cell lung cancer discuss the overall treatment landscape and look at recent data in the context of clinical guidelines.

Recent Advances in Treating Endometrial and Cervical Cancers

October 31st 2023

A panel of experts in gynecologic oncology explore advancements in the treatment of endometrial and cervical cancers, including breaking clinical trial data from ESMO 2023, and their potential impact on clinical practice.

ESMO 2023: Expert Perspectives & Insights into the Testing and Treatment of Melanoma

October 31st 2023

A panel of experts discusses updates in metastatic melanoma biomarker testing and treatment presented at ESMO Congress 2023 and other recent meetings and reviews the data in the context of existing guidelines, the current treatment landscape, and its impact on clinical practice.

Optimizing Therapy for Patients with Advanced Renal Cell Carcinoma

October 30th 2023

Expert panelists review recent updates in the treatment of advanced RCC following recent updates from the ESMO 2023 annual meeting and consider how they would approach specific scenarios in clinic.

Antibody-Drug Conjugates in Cancer Treatment

September 29th 2023

A panel of medical oncologists, nurse practitioners, and nurses specializing in breast, lung, and gastric cancers have a comprehensive discussion on antibody-drug conjugates, molecular testing, and best practices for treating patients.

A Review of Unmet Needs and Ways to Provide Optimal Care in Multiple Myeloma

August 21st 2023

Expert panelists highlight some of the most critical unmet needs in multiple myeloma and consider how to provide optimal care for patients globally.

Advances in Biomarker Testing and Targeted Therapies in NSCLC

August 15th 2023

A panel of expert oncologists have a detailed discussion on emerging biomarkers, molecular testing strategies, and the evolving targeted treatment landscape in non–small cell lung cancer.

Optimizing Homologous Recombination Deficiency (HRD) Testing Paradigms in Ovarian Cancer

July 17th 2023

Thomas Herzog, MD, Thomas Krivak, MD, and Ian Hagemann, MD, PhD discuss the biological mechanisms behind homologous recombination deficiency (HRD) in ovarian cancer and expand on best practices for somatic and germline HRD testing and results-based patient management in the clinic.

Updates in Treatment Approaches for Ovarian and Endometrial Cancers

June 29th 2023

An expert panel of gynecologic oncologists reviews recent data from the 2023 ASCO Annual Meeting and discusses the evolving treatment landscape.

HER2+ Breast Cancer: Recent Data Updates and Key Advances

June 29th 2023

A panel of experts summarizes the current treatment landscape for early and metastatic HER2+ breast cancer and discusses recent data updates in these settings, including those presented at the 2023 American Society of Clinical Oncology (ASCO) meeting.